

Androstanediol Glucuronide:

A metabolite of dihydrotestosterone formed in the peripheral tissues; plasma and urinary concentrations are used to estimate peripheral androgen activity.

Androstenedione:

Produced by the testes, adrenal cortex and ovaries. Androstenedione can be converted metabolically to testosterone and other androgens.

Dehydroepiandrosterone (DHEA):

Produced primarily in the adrenal cortex, from the steroid precursor pregnenolone. It is the major precursor in females and is metabolically converted to estradiol and testosterone. It is often present in excessive amounts in body fluids of patients with adrenal virilism.

Dehydroepiandrosterone-Sulfate (DHEA-S):

DHEA circulates in the bloodstream mainly as DHEA-sulfate (DHEA-S) prolonging its half life and providing a steady state source for conversion to estrogens and androgens. DHEA-S is a weak androgen which is measured in women exhibiting symptoms of virilism or hirsutism. It is also in children with precocious puberty.

Estradiol, 17β:

The most abundant and potent estrogen produced mainly in the ovaries, with secondary production by the adrenal glands. It is responsible for secondary female sex characteristics and prepares the uterus for implantation of the fertilized ovum.

Estriol:

produced almost exclusively during pregnancy by oxidation of estradiol and estrone. It is the major estrogen produced in the normal human fetus.

Estrone:

Produced primarily from androstenedione. In premenopausal women, more than 50% of the estrone is secreted by the ovaries. In prepubertal children, men and non-supplemented postmenopausal women the major portion of estrone is derived from peripheral metabolism of androstenedione.

Pregnenolone:

Pregnenolone (3β-hydroxypregn-5-en-20-one) is the first steroid to be derived from cholesterol in the pathway of steroidogenesis, and it is the common precursor for all of the adrenal and gonadal steroids.

Progesterone:

Produced directly from pregnenolone and secreted by the corpus luteum and by the placenta. It is responsible for changes associated with luteal phase of the menstrual cycle, differentiation factor for mammary glands, preparing the body for pregnancy and, if pregnancy occurs, maintaining it until birth.

Progesterone, 17α Hydroxy:

An intermediate in the biosynthesis of cortisol. Deficiency of either 11β- or 21-hydroxylase activities leads to an increased concentration of 17α-hydroxyprogesterone in the peripheral circulation.

Testosterone:


Principal androgen synthesized by the testes, produced from progesterone. Secretion increases sharply at puberty and is responsible for secondary male sex characteristics. Sperm production relies on the presence of testosterone.

5α-Dihydrotestosterone:

A metabolite of testosterone that is thought to be the more potent androgen responsible for formation of primary sex characters in males during embryogenesis, for development of most male secondary sex characters at puberty, and for adult male sexual function.

SHBG:

Sex hormone-binding globulin (SHBG) is a glycoprotein synthesized by the liver. Circulating androgen and estrogen concentrations influence SHBG synthesis. In men, 44-65% of circulating testosterone is bound to SHBG with high affinity. Alterations in SHBG concentrations may result in variations in total circulating steroid levels.



- Androstanediol Glucuronide (3α Diol-G)
- Androstenedione
- DHEA
- DHEA-S
- Estrone (E1)
- Estradiol, 17β (E2)
- Progesterone
- Progesterone, 17α Hydroxy
- Testosterone
- Free Testosterone
- 5α-Dihydrotestosterone
- Sex Hormone Binding Globulin (SHBG)*

Direct Assay
High Specificity
High Sensitivity
Short Incubation Time

* Not distributed in Belgium and Germany



Androstenediol Glucuronide (3 α Diol-G)	Androstenedione	DHEA	DHEA-S	Estrone (E1)	Estradiol, 17 β (E2)	Progesterone	17 α OH Progesterone	Testosterone	Free Testosterone	5 α -Dihydro-testosterone	Sex Hormone Binding Globulin (SHBG)*
--	-----------------	------	--------	--------------	----------------------------	--------------	-----------------------------	--------------	-------------------	----------------------------------	--------------------------------------

Application

<ul style="list-style-type: none"> Hirsutism Excessive adrenal androgen production 	<ul style="list-style-type: none"> Hirsutism Congenital adrenal hyperplasia (CAH) Androgen-secreting adrenal and ovarian tumor Polycystic ovary syndrome (POCS) 	<ul style="list-style-type: none"> Adrenal hyperplasia Hirsutism 	<ul style="list-style-type: none"> Adrenal tumor Hirsutism / Virilism Differentila diagnosis of Cushing's syndrome Congenital adrenal hypoplasia (CAH) Precocious puberty 	<ul style="list-style-type: none"> Fertility assesement Amenorrhea Ovarian malfunction Estrogen secreting tumors Precocious puberty in females 	<ul style="list-style-type: none"> Fertility assesement Menstrual cycle irregularities Estrogen secreting tumors Monitoring of osteoporosis in menopause In-vitro fertilization Precocious puberty in females 	<ul style="list-style-type: none"> Disorders of the ovaries or placenta Corpus luteum insufficiency Tracking of ovulation Suspected ectopic or failing pregnancy Monitoring the health of pregnancy Infertility Osteoporosis 	<ul style="list-style-type: none"> Congenital adrenal hyperplasia Monitoring steroid replacement therapy Prostatic cancer 	<ul style="list-style-type: none"> Male hypogonadism Delayed or precocious puberty Erectile dysfunction Hirsutism/Virilism Polycystic ovary syndrome (PCOS) 	<ul style="list-style-type: none"> Hirsutism/Virilism Hyperthyroidism Obesity Hyperinsulism 	<ul style="list-style-type: none"> Klinefelter syndrome Hirsutism Begnin prostate hyperplasia (BPH) 5α-reductase deficiency 	<ul style="list-style-type: none"> Hirsutism/Virilism Polycistic ovary syndrome (PCOS) Male hypogonadsim Obesity
--	---	--	--	---	---	--	--	--	---	---	--

Method

RIA CT	RIA CT	RIA	IRMA
--------	--------	-----	------

Kit Size

96 Tests	96 Tests	100 Tests
----------	----------	-----------

Catalog

KIP0151	KIP0451	KIP0491	KIP0481	KIP19100	KIP0629	KIP1458	KIP1409	KIP1709	KIP19000	KIP19900	RVR-CC-100
---------	---------	---------	---------	----------	---------	---------	---------	---------	----------	----------	------------

Incubation Time

2h RT	1h RT	2h RT	1h 37°C	2h RT	3h 37°C	2h 37°C	3h 37°C	3h 37°C	2h 37°C	30 min /1h/15 min. RT	1h 30 min. RT
-------	-------	-------	---------	-------	---------	---------	---------	---------	---------	-----------------------	---------------

Sample Type

serum plasma	serum plasma	serum	serum	serum plasma	serum plasma	serum	serum plasma	serum	serum plasma	serum
--------------	--------------	-------	-------	--------------	--------------	-------	--------------	-------	--------------	-------

Sample Size

100 μ L	25 μ L	200 μ L	20 μ L	100 μ L	50 μ L	25 μ L	50 μ L	300 μ L	20 μ L (must be diluted 1/51)
-------------	------------	-------------	------------	-------------	------------	------------	------------	-------------	-----------------------------------

Standard Range

0.2-75 ng/mL	0.1-11 ng/mL	0.2-40 ng/mL	1.6-800 μ g/dL	12.5-750 pg/mL	10-3551pg/mL	0.12-36 ng/mL	0.15-11,1 ng/mL	0.11-16.4 ng/mL	0.25-65 pg/mL	25-2500 pg/mL	10-250 nmol/L
--------------	--------------	--------------	--------------------	----------------	--------------	---------------	-----------------	-----------------	---------------	---------------	---------------

Detection Limit

0.05 ng/mL	0.03 ng/ml	0.1 ng/mL	0.59 μ g/dL	3.2 pg/mL	2 pg/mL	0,05 ng/mL	0.02 ng/mL	0.05 ng/mL	0.13 pg/mL	20 pg/mL	0.26 nmol/L
------------	------------	-----------	-----------------	-----------	---------	------------	------------	------------	------------	----------	-------------

Reference Intervals

Female: 0,3-9,3 ng/mL Male: 1,0-23,6 ng/mL	Female: 0,5-4,7 ng/mL Male: 0,5-4,8 ng/mL	under evaluation	Female 40-44: 37-256 μ g/dL Male 15-50: 81-479 μ g/dL	Female: 10-300 pg/mL Male: 10-60 pg/mL	Female: 6-488 pg/mL Male: 15-47 pg/mL	Female: 0,43-17,56 ng/mL Male: 0,6-2,11 ng/mL	Female: 0,11-5 ng/mL Male: 0,6-3,44 ng/mL	Female: <0,06-0,79 ng/mL Male: 1,34-6,25 ng/mL	Female: 0,02-3,09 pg/mL Male: 8,9-42,5 pg/mL	20 pg/mL	Female: 20-85 nmol/L Male : 9-55 nmol/L
---	--	------------------	--	---	--	--	--	---	---	----------	--

Controls

2 levels	2 levels	1 level
----------	----------	---------

Shelf Life

10 weeks	8 weeks	10 weeks	12 weeks	10 weeks	10 weeks	8 weeks	12 weeks	8 weeks
----------	---------	----------	----------	----------	----------	---------	----------	---------

* Not distributed in Belgium and Germany